drugset / Trial / NCT06864988
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Timeline
- Start
- 2025-03-03
- Primary completion
- 2027-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 4D-150 | Gene therapy (AAV / viral vector) | 3e+10 vg | Intravitreal |
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |